Pfizer: Melanoma trials

The registry lists 52 Melanoma studies with Pfizer as lead sponsor. 1 are open to participants now and 23 have results posted.

Phase 1 33Phase 2 19Phase 3 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study of PF-08046033 in Advanced Solid TumorsRecruitingNCT07519655Phase 1
• A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial SettingsCompletedNCT05954546Results posted
• Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the USCompletedNCT05260684Results posted
• Study of PF-07263689 in Participants With Selected Advanced Solid TumorsTerminatedNCT05061537Phase 1Results posted
• A Study of SEA-CD40 Given With Other Drugs in CancersCompletedNCT04993677Phase 2Results posted
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementTerminatedNCT04543188Phase 1Results posted
• A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsTerminatedNCT04032704Phase 2Results posted
• An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain MetastasisTerminatedNCT03911869Phase 2Results posted
• Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid TumorsCompletedNCT03864042Phase 1Results posted
• PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsTerminatedNCT03685591Phase 1Results posted
• A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid TumorsCompletedNCT02573259Phase 1Results posted
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)TerminatedNCT02554812Phase 1/2Results posted
• Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedNCT02315066Phase 1Results posted
• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaCompletedNCT01909453Phase 3Results posted
• LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF MelanomaTerminatedNCT01820364Phase 2Results posted
• A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal MelanomaTerminatedNCT01801358Phase 1/2Results posted
• A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant MelanomaCompletedNCT01781572Phase 1/2Results posted
• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.TerminatedNCT01777776Phase 1/2Results posted
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaCompletedNCT01763164Phase 3Results posted
• A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaCompletedNCT01436656Phase 1Results posted
• A Phase II Study of Single Agent MEK162 in Patients With Advanced MelanomaCompletedNCT01320085Phase 2Results posted
• A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
• Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic MelanomaCompletedNCT00094107Phase 2Results posted
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesTerminatedNCT06974734Phase 1
• A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersTerminatedNCT06870487Phase 1
• A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid TumorsTerminatedNCT06799533Phase 1
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerTerminatedNCT06580938Phase 1
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationTerminatedNCT06448364Phase 1
• A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1
• A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2
• A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsTerminatedNCT05571839Phase 1
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsActive, not recruitingNCT05538130Phase 1
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Active, not recruitingNCT05355701Phase 1
• A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaActive, not recruitingNCT04657991Phase 3
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
• Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
• A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
• A Study of SGN-CD228A in Advanced Solid TumorsTerminatedNCT04042480Phase 1
• A Safety Study of SGN-CD47M in Patients With Solid TumorsTerminatedNCT03957096Phase 1
• Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant MelanomaTerminatedNCT03878719Phase 1
• Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedNCT02890368Phase 1
• Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
• A Study of MEK162 and AMG 479 in Patients With Selected Solid TumorsTerminatedNCT01562899Phase 1/2
• Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic MelanomaCompletedNCT01435369Phase 2
• Treatment Use Study for Advanced Melanoma.No longer availableNCT00584493
• Use of 852A in Metastatic Cutaneous Melanoma.CompletedNCT00189332Phase 2
• MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.TerminatedNCT00147550Phase 1/2
• Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin LesionsCompletedNCT00091689Phase 1
• CPG 7909 Injection in MelanomaCompletedNCT00070642Phase 2
• PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)CompletedNCT00043368Phase 2